Page 2 - Mindset Pharma News Today

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

As the first large pharma operation to make a significant investment in psychedelics, the rewards could be big.

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE:CYBN) and UK-ba...

Otsuka Pharmaceutical Co. Ltd. announced plans to acquire Mindset Pharma Inc. for C$80 million (US$50.76 million) in an all-cash deal that will see Otsuka strengthen its neurology and psychiatric pipeline. Mindset, of Toronto, is developing next-generation psychedelic therapeutics to treat psychiatric and neurological disorders with high unmet needs.

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has agreed to be acquired by Otsuka Pharmaceutical Co, Ltd, through its wholly-owned Otsuka...

Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement by which Otsuka America Inc., the U.S. arm of Otsuka Pharmaceutical Co., would acquire all its outstanding shares in an all-cash transaction for approximately $60 (CA$80) million.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022 ... -Today at 07:43 am- MarketScreener

One investor predicts many companies will go bankrupt, and while some will merge with other distressed companies or form joint ventures.

As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also filed a patent application over a proprietary polymorph, 

As Reunion Neuroscience REUN and Mindset Pharma MSSTF continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran…